Company: DGLY
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021680
Chunk: 193

Company: DIGITAL ALLY, INC.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 8
Chunk 193
---
 of Common Stock sold in the offering, (ii) up to 15.0% of the number of Series A warrants sold in
the offering and (iii) up to 15.0% of the number of Series B warrants sold in the offering. The Underwriter may exercise this option
in whole or in part at any time within forty-five calendar days after the date of the final prospectus relating to the offering. The
Underwriter may exercise the over-allotment option with respect to shares of Common Stock only, Series A and Series B warrants only,
or any combination thereof. The purchase price to be paid per additional share of Common Stock will be equal to the public offering price
of one Unit (less $0.00001 allocated to each Series A and Series B warrants), as applicable, less the underwriting discount, and the
purchase price to be paid per over-allotment Series A and Series B warrants will be $0.00001. On February 14, 2025, the Underwriter exercised
its over-allotment option with respect to 3,000 pre-funded warrants/common shares, 7,500 Series A warrants and 7,500 Series B warrants.
Settlement occurred on April 17, 2025.

Aegis
Capital Corp. served as the sole book-running manager in the offering, pursuant to the terms of the Underwriting Agreement, and received
seven percent (7%) of the aggregate purchase price paid by investors in the offering, a one percent (1%) non-accountable expense and
reimbursement of the legal fees of its counsel.

The
units and pre-funded units were offered by the Company pursuant to an effective registration statement on Form S-1, as amended, which
was declared effective by the SEC on February 12, 2025. The final prospectus relating to the offering was filed with the SEC on February
13, 2025.

The
aggregate net proceeds to the Company from the offering including the underwriters exercise of their overallotment option were approximately
$14,308,300, after deducting underwriter’s fees and the payment of other offering expenses associated with the offering payable
by the Company.

2024
Issuance of Restricted Common Stock

In
January 2024, the board of directors approved the grant of 27 shares of Common Stock to officers of the Company. Such shares will generally
vest over a period of one to five years on their respective anniversary dates in January through January